We’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
ORION: A Global Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009)
Lead Author: Anne-Marie Wills, MD
Published: International Parkinson and Movement Disorder Society
Date: October 1, 2024
Biological Effects of Sodium Phenylbutyrate and Taurursodiol in Alzheimer's Disease
Lead Author: Steven E. Arnold
Published: Alzheimer’s & Dementia: Translational Research & Clinical Interventions, a journal of the Alzheimer’s Association
Date: August 9, 2024
Preclinical Development of AMX0114, an Antisense Oligonucleotide Targeting Calpain-2
Lead Author: Evan Mizerak (Presenter)
Published: Oligonucleotides for CNS Summit
Date: July 10, 2024
Learnings from the CENTAUR and PHOENIX Trials: Biomarker Results
Lead Author: Sabrina Paganoni, MD, PhD (Presenter)
Published: European Network to Cure ALS (ENCALS) Meeting 2024
Date: June 17 - 20, 2024
Results From the Global Phase 3 Trial Evaluating Sodium Phenylbutyrate and Ursodoxicoltaurine in ALS
Lead Author: Leonard H. van den Berg, MD, PhD, and Sabrina Paganoni, MD, PhD (Presenters)
Published: European Network to Cure ALS (ENCALS) Meeting 2024
Date: June 17 - 20, 2024
Updates on Development of AMX0114: An Antisense Oligonucleotide Inhibitor of Calpain-2, a Critical Effector of Axonal Degeneration
Lead Author: Lauren Kett, MD, PhD (Presenter)
Published: European Network to Cure ALS (ENCALS) Meeting 2024
Date: June 17 - 20, 2024
Understanding Treatment Barriers and Adherence Among People Living with Amyotrophic Lateral Sclerosis in Real World Clinical Practice
Lead Author: Genevieve Matte, MDCM, FRCP (Presenter)
Published: 2024 Canadian Neurological Sciences Federation (CNSF) Congress
Date: May 20 - 26, 2024
Assessment of AMX0114, An Antisense Oligonucleotide Targeting Calpain-2, in Multiple Models of Axonal Degeneration
Lead Author: Evan Mizerak (Presenter)
Published: TIDES USA | Oligonucleotide & Peptide Therapeutics
Date: May 14 - 17, 2024
Results From a Global Phase 3 Trial Evaluating an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis
Lead Author: Leonard H van den Berg, MD, PhD (Presenter)
Published: American Academy of Neurology Annual Meeting 2024
Date: April 13 - 18, 2024
ORION: A Global, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy
Lead Author: Günter Höglinger, MD (Presenter)
Published: AD/PD 2024 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD)
Date: March 5 - 9, 2024